Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 4
Submit an article Journal homepage
212
Views
0
CrossRef citations to date
0
Altmetric
Review

Recent advances in bacillus Calmette–Guerin immunotherapy in bladder cancer

Anton B Alexandroff1 Department of Dermatology, Leicester Royal Infirmary, LeicesterLE1 5WW, UKCorrespondence[email protected]
,
Steve Nicholson1 Department of Dermatology, Leicester Royal Infirmary, LeicesterLE1 5WW, UK
,
Poulam M Patel2 Academic Oncology, University of Nottingham, Nottingham, UK
&
Andrew M Jackson2 Academic Oncology, University of Nottingham, Nottingham, UK
Pages 551-560 | Published online: 16 Jul 2010

Bibliography

  • Alexandroff AB , JamesK: Immunotherapy of bladder cancer. In: Cancer Vaccines and Immunotherapy. Stern PL, Berverley P, Carroll MW (Eds).Cambridge University Press, UK, 19–46 (2000).
  • Alexandroff AB , JacksonAM, O‘DonnellMA, JamesK: BCG immunotherapy of bladder cancer: 20 years on.Lancet353(9165) , 1689–1694 (1999).
  • Centanni E , RezzesiF: Studio sperimentale sull‘antagonismo fra tuberculosi e carno.Rif. Med.42 , 195–200 (1926).
  • Holmgren I : La tuberculine di le BCG chez les concereux.Schweiz. Med. Wochenschr.65 , 1203–1206 (1935).
  • Mathe G , AmielJL, SchwarzenbergLet al.: Active immunotherapy for acute lymphoblastic leukaemia.Lancet1(7597) , 697–699 (1969).
  • Morales A , EidingerD, BruceAW: Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors.J. Urol.116(2) , 180–183 (1976).
  • Lamm DL , ThorDE, HarrisSC, ReynaJA, StogdillVD, RadwinHM: bacillus Calmette–Guerin immunotherapy of superficial bladder cancer.J. Urol.124(1) , 38–40 (1980).
  • Lamm DL , BlumensteinBA, CrawfordDet al.: Randomised intergroup comparison of Bacillus Calmette–Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder.Urol. Oncol.1 , 119–126 (1995).
  • Hussain MH , WoodDP, BajorinDFet al.: Bladder cancer: narrowing the gap between evidence and practice.J. Clin. Oncol.27(34) , 5680–5684 (2009).
  • Shelley MD , MasonMD, KynastonH: Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.Cancer Treat. Rev.36(3) , 195–205 (2010).
  • Shelley MD , CourtJB, KynastonH, WiltTJ, FishRG, MasonM: Intravesical bacillus Calmette–Guerin in Ta and T1 bladder cancer.Cochrane Database Syst. Rev. (4) , CD001986 (2000).
  • Shelley MD , CourtJB, KynastonH, WiltTJ, ColesB, MasonM: Intravesical Bacillus Calmette–Guerin versus mitomycin C for Ta and T1 bladder cancer.Cochrane Database Syst. Rev. (3) , CD003231 (2003).
  • Malmstrom PU , SylvesterRJ, CrawfordDEet al.: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guerin for non-muscle-invasive bladder cancer.Eur. Urol.56(2) , 247–256 (2009).
  • Sylvester RJ , van der Meijden AP, Witjes JA, Kurth K: Bacillus Calmette–Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol.174(1) , 86–91 (2005).
  • Babjuk M , OosterlinckW, SylvesterR, KaasinenE, BohleA, Palou-RedortaJ: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.Eur. Urol.54(2) , 303–314 (2008).
  • Joudi FN , SmithBJ, O‘DonnellMA: Final results from a national multicenter Phase II trial of combination bacillus Calmette–Guerin plus interferon α-2B for reducing recurrence of superficial bladder cancer.Urol. Oncol.24(4) , 344–348 (2006).
  • Gallagher BL , JoudiFN, MaymiJL, O‘DonnellMA: Impact of previous bacille Calmette–Guerin failure pattern on subsequent response to bacille Calmette–Guerin plus interferon intravesical therapy.Urology71(2) , 297–301 (2008).
  • Skolarus TA , LeeEW, VirgoKSet al.: Intravesical bacille Calmette–Guerin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy.J. Am. Coll. Surg.209(2) , 248–253 (2009).
  • Berglund RK , SavageCJ, VoraKC, KurtaJM, CroninAM: An analysis of the effect of statin use on the efficacy of bacillus Calmette–Guerin treatment for transitional cell carcinoma of the bladder.J. Urol.180(4) , 1297–1300 (2008).
  • Kresowik TP , GriffithTS: Bacillus Calmette–Guerin immunotherapy for urothelial carcinoma of the bladder.Immunotherapy.1(2) , 281–288 (2009).
  • Colombel M , SaintF, ChopinD, MalavaudB, NicolasL, RischmannP: The effect of ofloxacin on bacillus Calmette–Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.J. Urol.176(3) , 935–939 (2006).
  • Sun HY , SinghN: Should intravesical bacillus Calmette–Guerin be employed in transplant recipients with bladder carcinoma?Transpl. Infect. Dis. DOI: 10.1111/j.1399-3062.2010. 00506.x (2010) (Epub ahead of print).
  • Becich MJ , CarrollS, RatliffTL: Internalization of bacille Calmette–Guerin by bladder tumor cells.J. Urol.145(6) , 1316–1324 (1991).
  • Luo Y , ChenX, O‘DonnellMA: Mycobacterium bovis bacillus Calmette–Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.Clin. Exp. Immunol.147(2) , 370–378 (2007).
  • Alexandrov AV , JacksonAM, RumyantsevAG: Mechanisms of modulation of intercellular adhesion molecules ICAMs.Immunologia (1) , 4–13 (1997).
  • Esuvaranathan K , AlexandroffAB, McIntyreMet al.: Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy.J. Urol.154(2 Pt 1) , 572–575 (1995).
  • Prescott S , JacksonAM, HawkyardSJ, AlexandroffAB, JamesK: Mechanisms of action of intravesical bacille Calmette–Guerin: local immune mechanisms.Clin. Infect. Dis.31(Suppl. 3) , S91–S93 (2000).
  • Zhang Y , KhooHE, EsuvaranathanK: Effects of bacillus Calmette–Guerin and interferon α-2B on cytokine production in human bladder cancer cell lines.J. Urol.161(3) , 977–983 (1999).
  • Sander B , DammO, GustafssonB, AnderssonU, HakanssonL: Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette–Guerin.J. Urol.156(2 Pt 1) , 536–541 (1996).
  • Alexandroff AB , JacksonAM, SkibinskaAet al.: Bladder cancer cells do not express co-stimulatory molecules B7-1, B7-2 and B7-3: evidence for the existence of an additional ligand for LFA-1.Int. J. Oncol.8(6) , 1273–1282 (1996).
  • Ikeda N , ToidaI, IwasakiA, KawaiK, AkazaH: Surface antigen expression on bladder tumor cells induced by bacillus Calmette–Guerin (BCG): a role of BCG internalization into tumor cells.Int. J. Urol.9(1) , 29–35 (2002).
  • Lattime EC , GomellaLG, McCuePA: Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells.Cancer Res.52(15) , 4286–4290 (1992).
  • See WA , ZhangG, ChenF, CaoY, LangenstroerP, SandlowJ: Bacille-Calmette Guerin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1.BJU. Int.103(12) , 1714–1720 (2009).
  • Jackson AM , AlexandroffAB, FlemingD, PrescottS, ChisholmGD, JamesK: Bacillus-Calmette–Guerin (BCG) organisms directly alter the growth of bladder-tumor cells.Int. J. Oncol.5(3) , 697–703 (1994).
  • Higuchi T , ShimizuM, OwakiAet al.: A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth.Cancer Immunol. Immunother.58(8) , 1245–1255 (2009).
  • Demangel C , BrittonWJ: Interaction of dendritic cells with mycobacteria: where the action starts.Immunol. Cell Biol.78(4) , 318–324 (2000).
  • Ramoner R , RieserC, HeroldMet al.: Activation of human dendritic cells by bacillus Calmette–Guerin.J. Urol.159(5) , 1488–1492 (1998).
  • Cheadle EJ , SelbyPJ, JacksonAM: Mycobacterium bovis bacillus Calmette–Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism.Immunology108(1) , 79–88 (2003).
  • Naoe M , OgawaY, TakeshitaKet al.: Bacillus Calmette–Guerin-pulsed dendritic cells stimulate natural killer T cells and γδT cells.Int. J. Urol.14(6) , 532–538 (2007).
  • Ratliff TL , RitcheyJK, YuanJJ, AndrioleGL, CatalonaWJ: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.J. Urol.150(3) , 1018–1023 (1993).
  • Simons MP , O‘DonnellMA, GriffithTS: Role of neutrophils in BCG immunotherapy for bladder cancer.Urol. Oncol.26(4) , 341–345 (2008).
  • Pryor K , GoddardJ, GoldsteinDet al.: Bacillus Calmette–Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.Br. J. Cancer71(4) , 801–807 (1995).
  • Luo Y , YamadaH, EvanoffDP, ChenX: Role of Th1-stimulating cytokines in bacillus Calmette–Guerin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.Clin. Exp. Immunol.146(1) , 181–188 (2006).
  • Ayari C , LaRueH, HovingtonHet al.: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette–Guerin immunotherapy.Eur. Urol.55(6) , 1386–1395 (2009).
  • Jackson AM , AlexandroffAB, KellyRWet al.: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette–Guerin (BCG) immunotherapy.Clin. Exp. Immunol.99(3) , 369–375 (1995).
  • Eto M , KogaH, NomaH, YamaguchiA, YoshikaiY, NaitoS: Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette–Guerin for superficial bladder tumors.Urol. Int.75(2) , 114–118 (2005).
  • Saint F , KurthN, MaillePet al.: Urinary IL-2 assay for monitoring intravesical bacillus Calmette–Guerin response of superficial bladder cancer during induction course and maintenance therapy.Int. J. Cancer107(3) , 434–440 (2003).
  • Watanabe E , MatsuyamaH, MatsudaKet al.: Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette–Guerin immunotherapy for carcinoma in situ of the bladder.Cancer Immunol. Immunother.52(8) , 481–486 (2003).
  • Magno C , MelloniD, GaliAet al.: The anti-tumor activity of bacillus Calmette–Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2.Immunol. Lett.81(3) , 235–238 (2002).
  • Sanchez-Carbayo M , UrrutiaM, RomaniR, HerreroM, Gonzalez de Buitrago JM, Navajo JA: Serial urinary IL-2, IL-6, IL-8, TNFα, UBC, CYFRA 21–1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Res.21(4B) , 3041–3047 (2001).
  • Kaempfer R , GerezL, FarbsteinHet al.: Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression.J. Clin.Oncol.14(6) , 1778–1786 (1996).
  • Alexandroff AB , JacksonAM, SkibinskaA, JamesK: Production of IL-5, a classical T(h)2 cytokine, following bacillus Calmette Guerin immunotherapy of bladder cancer.Int. J. Oncol.9(1) , 179–182 (1996).
  • Peuchmaur M , VieillefondA, BenoitG, JardinA: [Analysis of lymphocyte subpopulations of the bladder following endovesical immunotherapy using BCG].Ann. Urol. (Paris)23(3) , 246–250 (1989).
  • Dethlefsen SM , MatsuuraN, ZetterBR: Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis.Invasion Metastasis14(1–6) , 395–408 (1994).
  • Siracusano S , VitaF, AbbateRet al.: The role of granulocytes following intravesical BCG prophylaxis.Eur. Urol.51(6) , 1589–1597 (2007).
  • Bohle A , ThanhauserA, UlmerAJ, ErnstM, FladHD, JochamD: Dissecting the immunobiological effects of bacillus Calmette–Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.J. Urol.150(6) , 1932–1937 (1993).
  • Jackson AM , HawkyardSJ, PrescottS, RitchieAW, JamesK, ChisholmGD: An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines.J. Urol.147(1) , 207–211 (1992).
  • Brandau S , SuttmannH, RiemensbergerJet al.: Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette–Guerin-activated killer cells.Clin. Cancer Res.6(9) , 3729–3738 (2000).
  • Alexandroff AB , JacksonAM, PatersonTet al.: Role for CD40-CD40 ligand interactions in the immune response to solid tumours.Mol. Immunol.37(9) , 515–526 (2000).
  • Jackson AM , AlexandrovAB, PrescottS, JamesK, ChisholmGD: Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.Immunology76(2) , 286–291 (1992).
  • Suttmann H , JochamD, BohleA, BrandauS: The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette–Guerin and interleukin 2-activated killer cells.Urol. Res.30(4) , 233–239 (2002).
  • Brandau S , BohleA: Activation of natural killer cells by bacillus Calmette–Guerin.Eur. Urol.39(5) , 518–524 (2001).
  • Suttmann H , JacobsenM, ReissK, JochamD, BohleA, BrandauS: Mechanisms of bacillus Calmette–Guerin mediated natural killer cell activation.J. Urol.172(4 Pt 1) , 1490–1495 (2004).
  • Durek C , BrandauS, UlmerAJ, FladHD, JochamD, BohleA: Bacillus-Calmette–Guerin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion.J. Urol.162(2) , 600–605 (1999).
  • Brandau S , RiemensbergerJ, JacobsenMet al.: NK cells are essential for effective BCG immunotherapy.Int. J. Cancer92(5) , 697–702 (2001).
  • Alexandroff AB , BlackJ, BollinaPR, JamesK: Differential production of γ/δ T cells in the urine of bladder cancer patients receiving bacillus Calmette–Guerin immunotherapy.Int. J. Oncol.10 , 387–393 (1997).
  • Gueguen M , PatardJJ, GauglerBet al.: An antigen recognized by autologous CTLs on a human bladder carcinoma.J. Immunol.160(12) , 6188–6194 (1998).
  • Simons MP , NauseefWM, GriffithTS: Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.Immunol. Res.39(1–3) , 79–93 (2007).
  • Ludwig AT , MooreJM, LuoYet al.: Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette–Guerin-induced antitumor activity.Cancer Res.64(10) , 3386–3390 (2004).
  • Zhang Y , KhooHE, EsuvaranathanK: Effects of bacillus Calmette–Guerin and interferon-α-2B on human bladder cancer in vitro.Int. J. Cancer71(5) , 851–857 (1997).
  • Brandau S , BohleA, ThanhauserAet al.: In vitro generation of bacillus Calmette–Guerin-activated killer cells.Clin. Infect. Dis.31(Suppl. 3) , S94–S100 (2000).
  • Jackson AM , AlexandrovAB, PrescottS, JamesK, ChisholmGD: Expression of adhesion molecules by bladder cancer cells: modulation by interferon-γ and tumour necrosis factor-α.J. Urol.148(5) , 1583–1586 (1992).
  • Jackson AM , PrescottS, HawkyardSJ, JamesK, ChisholmG: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.Cancer Immunol. Immunother.36(1) , 25–30 (1993).
  • Hawkyard SJ , JacksonAM, PrescottS, JamesK, ChisholmGD: The effect of recombinant cytokines on bladder cancer cells in vitro.J. Urol.150(2 Pt 1) , 514–518 (1993).
  • Alexandroff AB , RobinsRA, MurrayA, JamesK: Tumour immunology: false hopes – new horizons?Immunol. Today19(6) , 247–250 (1998).
  • Cooke PW , JamesND, GanesanR, WallaceM, BurtonA, YoungLS: CD40 expression in bladder cancer.J. Pathol.188(1) , 38–43 (1999).
  • O‘Donnell MA , LuoY, ChenX, SzilvasiA, HunterSE, ClintonSK: Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette–Guerin.J. Immunol.163(8) , 4246–4252 (1999).
  • Luo Y , ChenX, DownsTM, DeWolfWC, O‘DonnellMA: IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette–Guerin immunotherapy.J. Immunol.162(4) , 2399–2405 (1999).
  • Martin-Orozco N , MuranskiP, ChungYet al.: T helper 17 cells promote cytotoxic T cell activation in tumor immunity.Immunity31(5) , 787–798 (2009).
  • Murugaiyan G , SahaB: Protumor vs antitumor functions of IL-17.J. Immunol.183(7) , 4169–4175 (2009).
  • Wilson NJ , BonifaceK, ChanJRet al.: Development, cytokine profile and function of human interleukin 17-producing helper T cells.Nat. Immunol.8(9) , 950–957 (2007).
  • Boniface K , BlomB, LiuYJ, de Waal MR: From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol. Rev.226 , 132–146 (2008).
  • Alexandroff AB , NovitskayaES, ArmstrongDJ: Psoriasis as a multisystem inflammatory disease. In: Columbus F (Ed.).Advances in Medicine and Biology. Nova Science (2010) (In Press).
  • Oppmann B , LesleyR, BlomBet al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.Immunity13(5) , 715–725 (2000).
  • Alexandroff AB , PauriahM, CampRD, LangCC, StruthersAD, ArmstrongDJ: More than skin deep - atherosclerosis as a systemic manifestation of psoriasis.Br. J. Dermatol.161 , 1–7 (2009).
  • Fietta P , DelsanteG: The effector T helper cell triade.Riv. Biol.102(1) , 61–74 (2009).
  • Louten J , BonifaceK, de Waal MR: Development and function of TH17 cells in health and disease. J. Allergy Clin. Immunol.123(5) , 1004–1011 (2009).
  • Zhu X , MulcahyLA, MohammedRAet al.: IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines.Breast Cancer Res.10(6) , R95 (2008).
  • Saban MR , SimpsonC, DavisCet al.: Discriminators of mouse bladder response to intravesical bacillus Calmette–Guerin (BCG).BMC Immunol.8 , 6 (2007).
  • Wang L , YiT, KortylewskiM, PardollDM, ZengD, YuH: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway.J. Exp. Med.206(7) , 1457–1464 (2009).
  • Banham AH , PowrieFM, Suri-PayerE: Foxp3+ regulatory T cells: current controversies and future perspectives.Eur. J. Immunol.36(11) , 2832–2836 (2006).
  • Tang Q , BluestoneJA: The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.Nat. Immunol.9(3) , 239–244 (2008).
  • Coombes JL , SiddiquiKR, Rancibia-CarcamoCVet al.: A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism.J. Exp. Med.204(8) , 1757–1764 (2007).
  • Khader SA , CooperAM: IL-23 and IL-17 in tuberculosis.Cytokine41(2) , 79–83 (2008).
  • Bettelli E , CarrierY, GaoWet al.: Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells.Nature441(7090) , 235–238 (2006).
  • Veldhoen M , HockingRJ, AtkinsCJ, LocksleyRM, StockingerB: TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.Immunity24(2) , 179–189 (2006).
  • Ayyoub M , DeknuydtF, RaimbaudIet al.: Human memory Foxp3+ Tregs secrete IL-17 ex vivo and constitutively express the T(h)17 lineage-specific transcription factor RORg t.Proc. Natl Acad. Sci. USA106(21) , 8635–8640 (2009).
  • Voo KS , WangYH, SantoriFRet al.: Identification of IL-17-producing Foxp3+ regulatory T cells in humans.Proc. Natl Acad. Sci. USA106(12) , 4793–4798 (2009).
  • Lee SJ , DrabikK, Van Wagoner NJ et al.: ICAM-1-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. J. Immunol.165(8) , 4658–4666 (2000).
  • Jackson AM , AlexandrovAB, GribbenSC, EsuvarnathanK, JamesK: Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy.Int. J. Cancer55(6) , 921–925 (1993).
  • Young DG , JacksonAM, JamesK: Purification and characterisation of soluble intercellular adhesion molecule-1 and its effect on cell-mediated cytolysis of bladder tumour cells.Biochem. Soc. Trans.25(2) , 365S (1997).
  • Alexandroff AB , Graham-BrownRAC: Report from the 67th Annual Meeting of American Academy of Dermatology.Br. J. Dermatol.162(1) , 12–21 (2010).
  • Buijtels PC , Willemse-ErixHF, PetitPLet al.: Rapid identification of mycobacteria by Raman spectroscopy.J. Clin. Microbiol.46(3) , 961–965 (2008).
  • Kreunin P , ZhaoJ, RosserC, UrquidiV, LubmanDM, GoodisonS: Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling.J. Proteome Res.6(7) , 2631–2639 (2007).
  • Ahirwar DK , AgrahariA, MandhaniA, MittalRD: Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy.Biomarkers14(4) , 213–218 (2009).
  • Ahirwar DK , MandhaniA, DharaskarA, KesarwaniP, MittalRD: Association of tumour necrosis factor-α gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette–Guerin immunotherapy.BJU Int.104(6) , 867–873 (2009).
  • Haley JL , YoungDG, AlexandroffA, JamesK, JacksonAM: Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-α.Immunology96(1) , 114–121 (1999).
  • Young SL , MurphyM, ZhuXWet al.: Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy.Int. J. Cancer112(4) , 653–660 (2004).
  • Heidecker L , BrasseurF, Probst-KepperM, GueguenM, BoonT, Van den Eynde BJ: Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J. Immunol.164(11) , 6041–6045 (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.